Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

The efficacy and safety of sibutramine for weight loss: a systematic review.

Arterburn DE, Crane PK, Veenstra DL.

Arch Intern Med. 2004 May 10;164(9):994-1003. Review.

PMID:
15136309
2.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

3.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
4.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
5.

Sibutramine: current status as an anti-obesity drug and its future perspectives.

Sharma B, Henderson DC.

Expert Opin Pharmacother. 2008 Aug;9(12):2161-73. doi: 10.1517/14656566.9.12.2161 . Review.

PMID:
18671470
6.

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.

Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J.

Arch Intern Med. 2004 Jul 12;164(13):1395-404. Review.

PMID:
15249348
7.

A review of the metabolic effects of sibutramine.

Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS.

Curr Med Res Opin. 2005 Mar;21(3):457-68. Review.

PMID:
15811215
8.

Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis.

de Lemos HP Jr, Atallah AN, de Lemos AL.

Sao Paulo Med J. 2008 Nov;126(6):342-6. Review.

9.

Sibutramine. A review of its contribution to the management of obesity.

McNeely W, Goa KL.

Drugs. 1998 Dec;56(6):1093-124. Review.

PMID:
9878996
10.

Weight management and current options in pharmacotherapy: orlistat and sibutramine.

Leung WY, Thomas GN, Chan JC, Tomlinson B.

Clin Ther. 2003 Jan;25(1):58-80. Review.

PMID:
12637112
11.

Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.

Viner RM, Hsia Y, Tomsic T, Wong IC.

Obes Rev. 2010 Aug;11(8):593-602. doi: 10.1111/j.1467-789X.2009.00651.x. Epub 2009 Nov 17. Review.

PMID:
19922432
12.
13.

The discovery and status of sibutramine as an anti-obesity drug.

Luque CA, Rey JA.

Eur J Pharmacol. 2002 Apr 12;440(2-3):119-28. Review.

PMID:
12007530
14.
15.

Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.

Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004096. Review.

PMID:
15674929
16.

The use of sibutramine in the management of obesity and related disorders: an update.

Tziomalos K, Krassas GE, Tzotzas T.

Vasc Health Risk Manag. 2009;5(1):441-52. Review.

17.

Sibutramine lost and found.

Bosello O, Carruba MO, Ferrannini E, Rotella CM.

Eat Weight Disord. 2002 Sep;7(3):161-7. Review.

PMID:
12452247
18.

Modern medical management of obesity: the role of pharmaceutical intervention.

Aronne LJ.

J Am Diet Assoc. 1998 Oct;98(10 Suppl 2):S23-6. Review.

PMID:
9787732
19.

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.

García Díaz E, Martín Folgueras T.

Nutr Hosp. 2011 May-Jun;26(3):451-7. doi: 10.1590/S0212-16112011000300004. Review.

20.

Cardiovascular risk-benefit profile of sibutramine.

Scheen AJ.

Am J Cardiovasc Drugs. 2010;10(5):321-34. doi: 10.2165/11584800-000000000-00000. Review.

Supplemental Content

Support Center